Telik's Proteasome Program Meets Preclinical Development Milestone
Posted on: Monday, 25 August 2008, 09:00 CDT
Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia.
The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an approved drug for the treatment of multiple myeloma, is based on this mechanism.
The company said that its proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over Bortezomib and other proteasome inhibitors.
James Keck, vice president of biology at Telik, said: "The potentially favorable profile of these compounds was achieved through the use of our Trap computational drug discovery technology. We are currently conducting activities necessary to select a potential development candidate."
Source: Datamonitor
Related Articles
- Proteolix Raises $79 Million in Series C Financing
- Nereus Pharmaceuticals Initiates Combination Clinical Trial for Proteasome Inhibitor NPI-0052 in Solid Tumors
- Drug Screen for Cancer Patients Found
- Nereus Pharmaceuticals Initiates Phase I Clinical Trial for Anti-Cancer Proteasome Inhibitor
- Cytotoxic Treatments Play a Critical Role in Modern Cancer Therapy - Target-Based Approaches for Discovering Novel Oncology Drugs
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- Take a Look at the Target-Based Approaches for Discovering Novel Oncology Drugs
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
User Comments (0)
RSS Feeds